Cogent Biosciences Inc (COGT) - News Archive

As the biotech sector grapples with economic headwinds, Cogent Biosciences Inc. stands at a pivotal juncture in its mission to advance targeted therapies for cancer. Despite its cumulative net loss of $242 million over...

Breaking New Ground in GIST Therapy: Cogent Biosciences Phase 3 PEAK Trial Completes Enrollment and Surpasses Interim Futility AnalysisIn a significant milestone for the fight against Gastrointestinal Stromal Tumors (GI...

Positive FDA Meeting for Cogent Biosciences Aligns Novel MS2D2 Patient Reported Outcome Measure for SUMMIT Trial: Enrollment on Track for Completion in Q2 2025 Cogent Biosciences recently announced a successful meeting...

In their recent announcement, Cogent Biosciences revealed additional clinical data from Part 1 of the SUMMIT trial, showcasing the potential of bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)...

In recent news, Cogent Biosciences, Inc. has shared positive updated lead-in data from their ongoing Phase 3 PEAK trial. The trial assesses the efficacy of bezuclastinib, a selective and potent KIT mutant inhibitor, in...

The realm of cancer therapeutics is ever-expanding with groundbreaking research constantly contributing to novel strategies and interventions, striving to enhance clinical outcomes. Prominent in this arena is the develo...

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisCogent Biosciences, a leading biotechnology company specializing in the dev...

Cogent Biosciences, a leading biotechnology company focusing on the development of precision therapies for genetically driven diseases, has recently announced the completion of an oversubscribed private placement, raisi...

Cogent Biosciences Announces Exciting Milestones for 2024 in Precision Therapies DevelopmentWALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 - Cogent Biosciences, Inc. (Nasdaq: COGT), a leading biotechnology company spe...

In a significant development in the field of rare diseases, Cogent Biosciences has recently announced positive initial data from its Phase 2 SUMMIT trial, featuring the investigational drug, Bezuclastinib. This breakthr...